Claim OwnershipBrilliant Board Review & CME
Subscribed: 2Played: 3
Subscribe
© 2025 Brilliant Board Review & CME
Description
🎙️ Brilliant Medicine: Your Internal Medicine Edge
Stay sharp, stay current, and stay confident with Brilliant Medicine — the go-to podcast for Internal Medicine and Family Medicine physicians, residents, nurse practitioners, and physician assistants.
Each episode delivers high-yield insights on the latest breakthroughs, practice-changing guidelines, and cutting-edge treatments in Internal Medicine — with just enough board review to keep your clinical reasoning razor-sharp.
We cut through the noise, simplify complex studies, and translate new data into actionable knowledge for your daily practice. Whether you're prepping for boards or staying ahead in clinic, hospital, or telemed — we've got your back.
🩺 Fast. Practical. Evidence-based.
This is the update your medical brain craves.
94 Episodes
Reverse
Send us a text 🧠 Clinical Context: Subclinical atrial fibrillation = asymptomatic episodes of AF detected by implantable monitors or Holters, lasting 6 minutes to 24 hours. Big Question: Should we anticoagulate these patients? 🧪 Study Highlights – ARTESiA Trial: Design: 4,012 patients (mean age 76.8), randomized to apixaban 5 mg BID vs ASA 81 mg daily. Inclusion: Age >55 with or without history of stroke/TIA; device-confirmed subclinical AF. 📈 Outcomes: Primary endpoint: Stroke or systemic...
Send us a text 🧠 Clinical Context Patients over 65 undergoing inpatient surgery face unique risks. Cognitive impairment, frailty, and increased vulnerability to delirium demand a proactive and nuanced approach to anesthesia and postoperative care. 🔍 Preoperative Priorities Age ≥65 and inpatient status should automatically trigger a frailty and cognitive assessmentEngage a multidisciplinary team early—geriatrics, anesthesia, surgery, and nursing🛌 Postoperative Delirium: A Common Pitfall Use de...
Send us a text 🧠 Clinical Context Hydrochlorothiazide (HCTZ) vs. Chlorthalidone—a classic cardio debate! ALHAT once hinted at chlorthalidone’s superiority, but did a modern head-to-head trial confirm that? Let's break it down. 🧪 Study Snapshot: The HEADS-UP Trial Design: Randomized, head-to-head trialPopulation: ~14,000 patients, age ≥65, already on HCTZ 25–50 mg + 1–2 antihypertensivesPrior CV disease: 15% had MI, stroke, or HFGroups:Continue HCTZSwitch to Chlorthalidone 12.5–25 mg dailyFoll...
Send us a text 🧠 Clinical Context GLP-1 receptor agonists have taken center stage for both type 2 diabetes and obesity management, but their gastric side effects are giving anesthesiologists pause. The ASA's recent guidance recommends holding these agents before surgery to reduce risks of gastroparesis, regurgitation, and pulmonary aspiration. 🔬 ASA Guidelines Overview Daily Dosing? Hold on the day of surgeryWeekly Dosing? Hold one week priorIf asymptomatic and held as above? Proceed as usual...
Send us a text 🧠 Clinical Context DOACs (Direct Oral Anticoagulants) have revolutionized anticoagulation—goodbye routine INRs, hello convenience. But while they’ve made our lives easier, they’re not always a fit for every scenario. Here's how to navigate the DOAC jungle. ✅ When DOACs Are Preferred Venous Thromboembolism (VTE)Atrial Fibrillation⚠️ Exclude patients with:Mechanical heart valvesRheumatic mitral valve disease (That’s why cardiologists note “non-rheumatic” AF in their documen...
Send us a text 🧠 Clinical Context: You're prepping a patient for non-cardiac surgery—what's their cardiovascular risk? Turns out, it’s not always about echo reports or cath results. It starts with a stairs test (sort of). Duke Activity Status Index (DASI) and METs >4 can tell you if the heart's got enough reserve.🚶♂️ “Can you walk up a flight of stairs without gasping?” If yes, you’re likely good to go!If functional status is poor or unknown, consider labs:BNP, pro-BNP, or troponin — but ...
Send us a text 🧠 Trial: DOAC started at 3 days vs 8–14 days post-stroke in AF patients. 📊 Results: No ↑ bleeding. No ↑ ischemic events. 🧩 Clinical Takeaway: Safe to start within 4 days in mild to moderate stroke. Still tailor based on infarct size and bleeding risk.
Send us a text 🧪 Study: Vitamin K2 (180 mcg) reduced nocturnal leg cramps in elderly. 📉 Results: Cramps/week ↓ from 3.6 → ~1 over 8 weeks. Safe and well-tolerated. 🧩 Clinical Takeaway: Consider a K2 trial in patients with chronic cramps — especially if sleep-disrupting. Avoid in patients on warfarin.
Send us a text 🧪 Study: TXA within 2 hrs of ICH did not reduce hematoma expansion. No benefit in functional outcome or mortality. ⚠️ Note: Slight ↑ in thromboembolic events (3% vs 1%). 🧩 Clinical Takeaway: No routine use for TXA in spontaneous ICH. Still potential niche use in select trauma cases.
Send us a text 🧠 Study: Compared transfusion thresholds of Hgb <8 vs <10 in subarachnoid hemorrhage. 📊 Findings: No difference in modified Rankin Score at 12 months. Fewer transfusions, fewer complications in <8 group. 🧩 Clinical Takeaway: Restrictive transfusion strategy is safe in neuro ICU. Less exposure = better outcomes.
Send us a text 🧪 Trials: RESHAPE-HF2: ↓ HF hospitalizations with transcatheter edge-to-edge repair vs medical therapy. MATTR: Transcatheter approach non-inferior to surgical repair. 🧩 Clinical Takeaway: Game-changing for patients too high risk for surgery. Less peri-op risk, faster recovery — mitral repair is heading the way of TAVR.
Send us a text 💊 Study: SURMOUNT-HF trial — patients with obesity and HFpEF. Tirzepatide = ↓ HF hospitalizations and ↑ quality of life. 📈 Benefits: Significant weight loss. Better metabolic profiles. GI side effects: ~6% (nausea, diarrhea). 🧩 Clinical Takeaway: A major contender for cardio-metabolic syndrome with HFpEF. More than just a diabetes or weight-loss drug.
Send us a text 🧪 Study: Patients ≥55 with no relapses in 5 yrs and no new lesions in 3 yrs may stop disease-modifying therapy (DMT). No significant difference in disability progression. 🧩 Clinical Takeaway: De-escalation strategy in stable MS may reduce cost and side effects. Still requires close neurology follow-up.
Send us a text 🧠 Clinical Tool: Spot urine sodium 2 hours after IV loop diuretic. If <50–70 mmol/L → inadequate response. Consider doubling dose or switching loop agents. 💡 Tips: Also assess urine output in first 6 hours (<100–150 mL/hr = poor response). Less helpful after 24 hrs or in chronic diuretic users. 🧩 Clinical Takeaway: Fast, practical guide to assess diuretic effectiveness in acute decompensated HF.
Send us a text 🧪 Key Findings: Cohort study: SGLT2 inhibitors led to significantly lower rates of nephrolithiasis compared to GLP-1 RAs. Mechanism: increased urinary flow and uric acid excretion. 🔢 Stats: NNT = 20 for prevention. NNT = 5 for recurrent stone formers. 🧩 Clinical Takeaway: Another bonus benefit of SGLT2 inhibitors. May sway decision in diabetics prone to stones. HCTZ no longer holds the same weight in stone prevention.
Send us a text 🧪 Key Insights: Observational data links semaglutide (GLP-1 RA) to increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). Incidence: ~9–15 cases per 100,000 patient-years. Possible mechanism: GLP-1 receptors in optic nerve ganglion cells. No proven causality yet — retrospective study only. 🧩 Clinical Takeaway: Risk remains very low. Discuss with patients who have eye disease or prior NAION before initiating therapy.
Send us a text 🧪 VOYAGER-PAD Trial: Patients with PAD post lower extremity revascularization. Rivaroxaban 2.5 mg BID + aspirin vs aspirin alone. 📈 Results: ↓ Major Adverse CV Events (MACE). ↓ Major Adverse Limb Events (MALE). Modest ↑ in bleeding — no ↑ in fatal bleeds. 🧩 Clinical Takeaway: Now guideline-endorsed for symptomatic PAD post-intervention. Risk-benefit conversation needed in high-bleed-risk patients.
Send us a text 🧠 Problem: RLS causes chronic sleep disruption, often worsens in hospital or peri-op settings. 💊 Management: First-line: Gabapentin or Pregabalin (per American Academy of Sleep Medicine). Avoid long-term dopamine agonists — cause augmentation and impulse control disorders. 🩸 Bonus Tip: Check ferritin — keep it >75 ng/mL. Oral or IV iron can help symptom control. 🧩 Clinical Takeaway: Treat aggressively; it’s more than “just annoying.” Avoid benzos and older agents unless no b...
Send us a text 🧪 Study: Retrospective look at patients with intracranial hemorrhage (ICH) on warfarin for mechanical valves. Followed for stroke, rebleed, mortality. 📈 Findings: Only 2 strokes in first 7 days after stopping warfarin. Most resumed warfarin around day 7 with low rebleed risk. ⚠️ Exclusions: Massive bleeds, unstable patients, large hematomas may require longer delay. 🧩 Clinical Takeaway: Restarting warfarin at 7 days appears safe in stable patients. Still a team-based call — inc...
Send us a text 📊 What It Is: A modern CV risk estimator developed from 2.3 million-person dataset. Replaces outdated ASCVD calculator (based on 25k). 🧠 Features: Adds BMI, GFR, A1C, and zip code. Omits race — more equitable. Outputs risk of heart disease, stroke, heart failure. ⚠️ Caveats: Generally gives lower risk estimates vs ASCVD. May reduce statin overuse, but some feel it's too conservative. 🧩 Clinical Takeaway: Helpful in primary prevention — especially borderline cases. Use side-by-s...
Comments
Download from Google Play
Download from App Store
United States